Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 26.24 -0.26 (-0.98%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Exelixis Inc < Previous 1 2 3 4 5 Next > Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine September 16, 2024 From Exelixis, Inc. Via Business Wire Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 September 15, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September August 28, 2024 From Exelixis, Inc. Via Business Wire 3 Stocks to Buy for a Soft Landing, If There Is One August 15, 2024 Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes Via MarketBeat Topics Economy Exposures Economy Interest Rates Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 06, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors August 06, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 July 23, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Present at the William Blair 44th Annual Growth Stock Conference May 28, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 20, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May May 07, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update April 30, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 April 16, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March February 27, 2024 From Exelixis, Inc. Via Business Wire Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies February 14, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update February 06, 2024 From Exelixis, Inc. Via Business Wire Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies February 14, 2024 From FN Media Group LLC Via GlobeNewswire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February February 01, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 January 25, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 January 23, 2024 From Exelixis, Inc. Via Business Wire Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma January 22, 2024 From Bristol Myers Squibb Via Business Wire European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets January 18, 2024 From Exelixis, Inc. Via Business Wire Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 January 07, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 January 02, 2024 From Exelixis, Inc. Via Business Wire Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 December 07, 2023 From Exelixis, Inc. Via Business Wire Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer December 04, 2023 From Exelixis, Inc. Via Business Wire Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma December 04, 2023 From Arcus Biosciences Via Business Wire Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment November 29, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 November 21, 2023 From Exelixis, Inc. Via Business Wire Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 November 10, 2023 From Exelixis, Inc. Via Business Wire Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update November 01, 2023 From Exelixis, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.